In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
M Barcena-VarelaDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0000-0001-7868-7939 J ShangMarc and Jennifer Lipshultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0000-0001-8274-1109 I MognoMarc and Jennifer Lipshultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0000-0002-8180-6609 I LieblingDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0009-0006-5482-9414 K R MeadMarc and Jennifer Lipshultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
Z LiMarc and Jennifer Lipshultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0009-0002-9991-5034 K E LindbladDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0000-0001-6093-5578 M Ruiz de GalarretaDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0000-0001-9666-8416 S GnjaticDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, USA.
M MeradMarc and Jennifer Lipshultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0000-0002-4481-7827 T JunDivision of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0000-0002-2120-1704 C AngDivision of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, USA.
T U MarronMarc and Jennifer Lipshultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0000-0001-5903-8191 J FaithMarc and Jennifer Lipshultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0000-0002-2691-4500 A LujambioDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0000-0002-2798-1481 Funding
Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4MTHE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4MTRAINING PROGRAM IN CANCER THERAPYT32CA078207 · NCI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI James J Manfredi · 1999 to 2026
$11.6MThe Influence Of Gut Microbiota Stability In Inflammatory Bowel DiseaseR01DK112978 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Jeremiah James Faith · 2019 to 2026
$5.3MTranslational Immunology Training ProgramT32AI078892 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Karen Leigh Edelblum, SERGIO A. LIRA · 2008 to 2026
$4.5MUncovering the rules of gut microbiome strain transmissionR01DK124133 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Jeremiah James Faith · 2020 to 2026
$4.2MTumor-intrinsic signaling pathways restrict anti-tumor immunity in hepatocellular carcinomaR37CA230636 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LUJAMBIO, AMAIA · 2018 to 2024
$2.7MCOVID and Translational Science supercomputer (CATS)S10OD030463 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2021 to 2021
$2.0MBig Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0MNCATS NIH HHS UL1 TR004419NCI NIH HHS P30 CA196521NCI NIH HHS R37 CA230636NCI NIH HHS T32 CA078207NIAID NIH HHS T32 AI078892NIDDK NIH HHS R01 DK112978NIDDK NIH HHS R01 DK124133NIH HHS S10 OD026880NIH HHS S10 OD030463
6 · The paper itselfAbstract
Background and Aims: Growing evidence highlight the critical role of the gut microbiome in tumorigenesis and response to immunotherapies. However, the impact of gut microbes on hepatocellular carcinoma (HCC) progression and response to immune-checkpoint blockade (ICB) remains unclear due to the lack of combined preclinical and clinical studies. Approach & Results: We performed 16S rRNA of cross-cohort stool samples from 10 HCC responders (R) and 40 non-responders (NR) to ICB at baseline and on-treatment time-points. We identified an enrichment of Conclusions: This study identified
Indexed as
antibiotics (ABXs)fecal microbiome transplant (FMT)gut microbiomeHepatocellular carcinoma (HCC)Immune checkpoint blockade (ICB)
Identifiers
PMID41415394
PMCPMC12710632
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390